SlideShare uma empresa Scribd logo
1 de 24
Baixar para ler offline
18F-FDGPET for Mediastinal Staging
         of Lung Cancer:
Which SUV Threshold Makes Sense?

                        Dirk Hellwig et al.
Department of Nuclear Medicine, Saarland University Medical Center,
                    Homburg/Saar, Germany
                 J Nucl Med 2007; 48:1761–1766




                             Resident: Apichaya Claimon, M.D.
                             Advisor: Pongpija Tuchinda, M.D.
Evaluation of mediastinal LN involvement

Mediastinoscopy & Excision
  Gold standard
  Sen 80%, Spec 100%
  Invasive
Contrast-enhanced CT & MRI
 Use size criteria
   to differentiate between benign & malignant
 But 21% of metastases are in normal sized LN

 40% of enlarged LN are no malignancy
18F-FDG   PET
 The most accurate noninvasive modality for
 staging mediastinal LN in lung cancer
Aim of the study
To determine optimum SUV threshold
  for mediastinal LN staging in patients with
  NSCLC


To compare diagnostic performance of
SUV analysis with visual interpretation
MATERIALS AND METHODS
Retrospective study
Patients with suspected NSCLC

                 18F-FDG   PET
                           within 6 wk


               Mediastinoscopy

Total 95 (75 men, 20 woman, age 62+9)
18F-FDG        PET LN evaluation
Visual
  Compare with mediastinal blood pool
  6 level (- - - to + + +)


SUV max
  1.5 cm ROI
  over visible LN or typical area of LN station
RESULT
Total 95



                 Lung CA 80                     Malig mesothelioma 2   Benign 11
                  (SCC 39, adeno 31,               Malig lymphoma 1           (TB 4,
                 unspecified NSCLC 4,                                  after pneumonia 2,
                   Carcinosarcoma 1,                                        silicosis 2,
                        SCLC 5)                         MFH 1             sarcoidosis 1)


                                         Total 371 nodes biopsy


 23/80 patient                70/311 nodes
                                        Positive
mediastinal LN metastasis
                                        (23%)
         (29%)
18F-FDG   PET in LN staging of lung cancer




     unaffected lymph nodes (N0)
     peribronchial or hilar lymph node involvement (N1)
     ipsilateral mediastinal and subcarinal involvement (N2)
     contralateral and supraclavicular involvement (N3)
Comparison of SUVmax in mediastinal LN




  SUVs were higher in metastatic lymph node stations (P < 0.01)
Tumor-free LN with inflammatory changes
had SUV = 2.7 + 2.0
(range, 0.8–14.9; n = 146)
Diagnostic performance

Using Visual Interpretation

Using SUV 2.5 as Cutoff Value
Using Visual Interpretation
Using Visual Interpretation
Using Visual Interpretation
Visual Interpretation vs. SUV Analysis
       AUC

  Visual
  0.930+0.022

  SUV
  0.899+0.025

   No significant
    (P = 0.241)
Determination of
Optimal SUV Threshold




 Minimal FNR + FPR at SUV = 2.5
 Highest diagnostic accuracy at SUV= 4.5
CONCLUSION
Human observation has higher sensitivity
than SUV analysis

But SUV has greater value in less
experience observer
SUV threshold = 2.5 is feasible
  For differentiating benign from metastatic
  mediastinal lymph nodes in lung CA patients
  Sen = 89%, Spec = 84%


False - : small metastasis
False + : LN inflammation
High NPV (96%)
  if PET –ve ; can omit mediastinoscopy


Highest diagnostic accuracy at SUV > 4.5

But SUV = 2.5 cannot applied to LN
metastasis in other tumor types
  Because differ 18F-FDG uptake
Using Visual Interpretation

Mais conteúdo relacionado

Mais procurados

Ulrassonagrafia de tórax em derrames pleurais
Ulrassonagrafia de tórax em derrames pleuraisUlrassonagrafia de tórax em derrames pleurais
Ulrassonagrafia de tórax em derrames pleurais
Flávia Salame
 
Plnd athens 2011
Plnd athens 2011Plnd athens 2011
Plnd athens 2011
erussociety
 

Mais procurados (20)

Spn
SpnSpn
Spn
 
Cirugía Radioguiada en Cáncer de Tiroides
Cirugía Radioguiada en Cáncer  de TiroidesCirugía Radioguiada en Cáncer  de Tiroides
Cirugía Radioguiada en Cáncer de Tiroides
 
Lung ca &amp; staging
Lung ca &amp; stagingLung ca &amp; staging
Lung ca &amp; staging
 
344.full
344.full344.full
344.full
 
Ulrassonagrafia de tórax em derrames pleurais
Ulrassonagrafia de tórax em derrames pleuraisUlrassonagrafia de tórax em derrames pleurais
Ulrassonagrafia de tórax em derrames pleurais
 
GANGLIO CENTINELA EN CIRUGIA DIGESTIVA
GANGLIO CENTINELA EN CIRUGIA DIGESTIVAGANGLIO CENTINELA EN CIRUGIA DIGESTIVA
GANGLIO CENTINELA EN CIRUGIA DIGESTIVA
 
CES2017-02: Lung Cancer
CES2017-02: Lung CancerCES2017-02: Lung Cancer
CES2017-02: Lung Cancer
 
2013 poggi anticancer research mw ablation of hcc using a new percutaneous de...
2013 poggi anticancer research mw ablation of hcc using a new percutaneous de...2013 poggi anticancer research mw ablation of hcc using a new percutaneous de...
2013 poggi anticancer research mw ablation of hcc using a new percutaneous de...
 
Cancer de pulmon uv
Cancer de pulmon uvCancer de pulmon uv
Cancer de pulmon uv
 
6 lungcancer
6 lungcancer6 lungcancer
6 lungcancer
 
Lung Cancer Video1
Lung Cancer Video1Lung Cancer Video1
Lung Cancer Video1
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 
CES 2016 02 - Lung Cancer
CES 2016 02 - Lung CancerCES 2016 02 - Lung Cancer
CES 2016 02 - Lung Cancer
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 
The principles of head and neck PET/CT
The principles of head and neck PET/CTThe principles of head and neck PET/CT
The principles of head and neck PET/CT
 
Plnd athens 2011
Plnd athens 2011Plnd athens 2011
Plnd athens 2011
 
CAR-T cell immunotherapy for solid tumors
CAR-T cell immunotherapy for solid tumorsCAR-T cell immunotherapy for solid tumors
CAR-T cell immunotherapy for solid tumors
 
CTNeT - Dr. Geyer Presentation CPRIT 2012
CTNeT - Dr. Geyer Presentation CPRIT 2012CTNeT - Dr. Geyer Presentation CPRIT 2012
CTNeT - Dr. Geyer Presentation CPRIT 2012
 
New TNM staging for lung cancer
New TNM staging for lung cancer New TNM staging for lung cancer
New TNM staging for lung cancer
 
Stem cell
Stem cellStem cell
Stem cell
 

Semelhante a 18F FDG PET For Mediastinal Staging

Positron Emission Tomography In Oncology
Positron Emission Tomography In OncologyPositron Emission Tomography In Oncology
Positron Emission Tomography In Oncology
fondas vakalis
 
Surgical persrective in lung cancer
Surgical persrective in lung cancerSurgical persrective in lung cancer
Surgical persrective in lung cancer
Harilal Nambiar
 

Semelhante a 18F FDG PET For Mediastinal Staging (20)

Non small cell lung cancer copy
Non small cell lung cancer   copyNon small cell lung cancer   copy
Non small cell lung cancer copy
 
Positron Emission Tomography In Oncology
Positron Emission Tomography In OncologyPositron Emission Tomography In Oncology
Positron Emission Tomography In Oncology
 
Biomarkers in head and neck cancers final ajeet
Biomarkers in head and neck cancers final ajeetBiomarkers in head and neck cancers final ajeet
Biomarkers in head and neck cancers final ajeet
 
FNAC lung (2).ppt
FNAC lung (2).pptFNAC lung (2).ppt
FNAC lung (2).ppt
 
Surgical persrective in lung cancer
Surgical persrective in lung cancerSurgical persrective in lung cancer
Surgical persrective in lung cancer
 
FNAC lung.ppt
FNAC lung.pptFNAC lung.ppt
FNAC lung.ppt
 
Head & neck cancer
Head & neck cancerHead & neck cancer
Head & neck cancer
 
Small cell lung cancer staging and management
Small cell lung cancer staging and  managementSmall cell lung cancer staging and  management
Small cell lung cancer staging and management
 
Lung cancer overview-JTL
Lung cancer overview-JTLLung cancer overview-JTL
Lung cancer overview-JTL
 
Lungs contouring Dr. Abani.pdf
Lungs contouring Dr. Abani.pdfLungs contouring Dr. Abani.pdf
Lungs contouring Dr. Abani.pdf
 
Lung plan evaluation
Lung plan evaluationLung plan evaluation
Lung plan evaluation
 
Barcelona Screening
Barcelona ScreeningBarcelona Screening
Barcelona Screening
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Echoendoscopic Lymph Node Staging in Lung Cancer: An endoscopic alternative
Echoendoscopic Lymph Node Staging in Lung Cancer: An endoscopic alternativeEchoendoscopic Lymph Node Staging in Lung Cancer: An endoscopic alternative
Echoendoscopic Lymph Node Staging in Lung Cancer: An endoscopic alternative
 
MCC 2011 - Slide 11
MCC 2011 - Slide 11MCC 2011 - Slide 11
MCC 2011 - Slide 11
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
 
20170417 Lung Neuroendocrine Tumor (NET) Review
20170417 Lung Neuroendocrine Tumor (NET) Review20170417 Lung Neuroendocrine Tumor (NET) Review
20170417 Lung Neuroendocrine Tumor (NET) Review
 
Elective Nodal Irradiation #radonc
Elective Nodal Irradiation #radoncElective Nodal Irradiation #radonc
Elective Nodal Irradiation #radonc
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
 
Lung Cancer Today: A Group Endavor
Lung Cancer Today: A Group EndavorLung Cancer Today: A Group Endavor
Lung Cancer Today: A Group Endavor
 

Mais de Apichaya Claimon

Mais de Apichaya Claimon (9)

Cp 50 10-18 2 blood gas and acid base balance
Cp 50 10-18 2  blood gas and acid base balanceCp 50 10-18 2  blood gas and acid base balance
Cp 50 10-18 2 blood gas and acid base balance
 
Cp 50 10-18 4 talk lab - class slide ha
Cp 50 10-18 4 talk lab - class slide haCp 50 10-18 4 talk lab - class slide ha
Cp 50 10-18 4 talk lab - class slide ha
 
Cp 50 10-18 2 blood gas and acid base balance
Cp 50 10-18 2  blood gas and acid base balanceCp 50 10-18 2  blood gas and acid base balance
Cp 50 10-18 2 blood gas and acid base balance
 
Cp 50 10-18 1 congenital & acquired ha
Cp 50 10-18 1 congenital & acquired haCp 50 10-18 1 congenital & acquired ha
Cp 50 10-18 1 congenital & acquired ha
 
Ap 50 11-12 1 orthopedic pathology
Ap 50 11-12 1 orthopedic pathologyAp 50 11-12 1 orthopedic pathology
Ap 50 11-12 1 orthopedic pathology
 
Ap 50 10-29 1 pathology of lung 1
Ap 50 10-29 1 pathology of lung 1Ap 50 10-29 1 pathology of lung 1
Ap 50 10-29 1 pathology of lung 1
 
Ap 50 10-22 1 diseases of infancy and childhood
Ap 50 10-22 1 diseases of infancy and childhoodAp 50 10-22 1 diseases of infancy and childhood
Ap 50 10-22 1 diseases of infancy and childhood
 
Ap 50 10-15 1 re system
Ap 50 10-15 1 re systemAp 50 10-15 1 re system
Ap 50 10-15 1 re system
 
Myocardial Perfusion SPECT coregistered Coronary CTA
Myocardial Perfusion SPECT coregistered Coronary CTAMyocardial Perfusion SPECT coregistered Coronary CTA
Myocardial Perfusion SPECT coregistered Coronary CTA
 

Último

SURVEY I created for uni project research
SURVEY I created for uni project researchSURVEY I created for uni project research
SURVEY I created for uni project research
CaitlinCummins3
 
The basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxThe basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptx
heathfieldcps1
 

Último (20)

ANTI PARKISON DRUGS.pptx
ANTI         PARKISON          DRUGS.pptxANTI         PARKISON          DRUGS.pptx
ANTI PARKISON DRUGS.pptx
 
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
 
Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17
Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17
Removal Strategy _ FEFO _ Working with Perishable Products in Odoo 17
 
ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...
ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...
ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...
 
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General QuizPragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
 
demyelinated disorder: multiple sclerosis.pptx
demyelinated disorder: multiple sclerosis.pptxdemyelinated disorder: multiple sclerosis.pptx
demyelinated disorder: multiple sclerosis.pptx
 
MichaelStarkes_UncutGemsProjectSummary.pdf
MichaelStarkes_UncutGemsProjectSummary.pdfMichaelStarkes_UncutGemsProjectSummary.pdf
MichaelStarkes_UncutGemsProjectSummary.pdf
 
philosophy and it's principles based on the life
philosophy and it's principles based on the lifephilosophy and it's principles based on the life
philosophy and it's principles based on the life
 
....................Muslim-Law notes.pdf
....................Muslim-Law notes.pdf....................Muslim-Law notes.pdf
....................Muslim-Law notes.pdf
 
The Last Leaf, a short story by O. Henry
The Last Leaf, a short story by O. HenryThe Last Leaf, a short story by O. Henry
The Last Leaf, a short story by O. Henry
 
How to Manage Closest Location in Odoo 17 Inventory
How to Manage Closest Location in Odoo 17 InventoryHow to Manage Closest Location in Odoo 17 Inventory
How to Manage Closest Location in Odoo 17 Inventory
 
Operations Management - Book1.p - Dr. Abdulfatah A. Salem
Operations Management - Book1.p  - Dr. Abdulfatah A. SalemOperations Management - Book1.p  - Dr. Abdulfatah A. Salem
Operations Management - Book1.p - Dr. Abdulfatah A. Salem
 
II BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING II
II BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING IIII BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING II
II BIOSENSOR PRINCIPLE APPLICATIONS AND WORKING II
 
REPRODUCTIVE TOXICITY STUDIE OF MALE AND FEMALEpptx
REPRODUCTIVE TOXICITY  STUDIE OF MALE AND FEMALEpptxREPRODUCTIVE TOXICITY  STUDIE OF MALE AND FEMALEpptx
REPRODUCTIVE TOXICITY STUDIE OF MALE AND FEMALEpptx
 
PSYPACT- Practicing Over State Lines May 2024.pptx
PSYPACT- Practicing Over State Lines May 2024.pptxPSYPACT- Practicing Over State Lines May 2024.pptx
PSYPACT- Practicing Over State Lines May 2024.pptx
 
SURVEY I created for uni project research
SURVEY I created for uni project researchSURVEY I created for uni project research
SURVEY I created for uni project research
 
An overview of the various scriptures in Hinduism
An overview of the various scriptures in HinduismAn overview of the various scriptures in Hinduism
An overview of the various scriptures in Hinduism
 
Features of Video Calls in the Discuss Module in Odoo 17
Features of Video Calls in the Discuss Module in Odoo 17Features of Video Calls in the Discuss Module in Odoo 17
Features of Video Calls in the Discuss Module in Odoo 17
 
The basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxThe basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptx
 
Spring gala 2024 photo slideshow - Celebrating School-Community Partnerships
Spring gala 2024 photo slideshow - Celebrating School-Community PartnershipsSpring gala 2024 photo slideshow - Celebrating School-Community Partnerships
Spring gala 2024 photo slideshow - Celebrating School-Community Partnerships
 

18F FDG PET For Mediastinal Staging

  • 1. 18F-FDGPET for Mediastinal Staging of Lung Cancer: Which SUV Threshold Makes Sense? Dirk Hellwig et al. Department of Nuclear Medicine, Saarland University Medical Center, Homburg/Saar, Germany J Nucl Med 2007; 48:1761–1766 Resident: Apichaya Claimon, M.D. Advisor: Pongpija Tuchinda, M.D.
  • 2. Evaluation of mediastinal LN involvement Mediastinoscopy & Excision Gold standard Sen 80%, Spec 100% Invasive
  • 3. Contrast-enhanced CT & MRI Use size criteria to differentiate between benign & malignant But 21% of metastases are in normal sized LN 40% of enlarged LN are no malignancy
  • 4. 18F-FDG PET The most accurate noninvasive modality for staging mediastinal LN in lung cancer
  • 5. Aim of the study To determine optimum SUV threshold for mediastinal LN staging in patients with NSCLC To compare diagnostic performance of SUV analysis with visual interpretation
  • 6. MATERIALS AND METHODS Retrospective study Patients with suspected NSCLC 18F-FDG PET within 6 wk Mediastinoscopy Total 95 (75 men, 20 woman, age 62+9)
  • 7. 18F-FDG PET LN evaluation Visual Compare with mediastinal blood pool 6 level (- - - to + + +) SUV max 1.5 cm ROI over visible LN or typical area of LN station
  • 9. Total 95 Lung CA 80 Malig mesothelioma 2 Benign 11 (SCC 39, adeno 31, Malig lymphoma 1 (TB 4, unspecified NSCLC 4, after pneumonia 2, Carcinosarcoma 1, silicosis 2, SCLC 5) MFH 1 sarcoidosis 1) Total 371 nodes biopsy 23/80 patient 70/311 nodes Positive mediastinal LN metastasis (23%) (29%)
  • 10. 18F-FDG PET in LN staging of lung cancer unaffected lymph nodes (N0) peribronchial or hilar lymph node involvement (N1) ipsilateral mediastinal and subcarinal involvement (N2) contralateral and supraclavicular involvement (N3)
  • 11. Comparison of SUVmax in mediastinal LN SUVs were higher in metastatic lymph node stations (P < 0.01)
  • 12. Tumor-free LN with inflammatory changes had SUV = 2.7 + 2.0 (range, 0.8–14.9; n = 146)
  • 13. Diagnostic performance Using Visual Interpretation Using SUV 2.5 as Cutoff Value
  • 17. Visual Interpretation vs. SUV Analysis AUC Visual 0.930+0.022 SUV 0.899+0.025 No significant (P = 0.241)
  • 18. Determination of Optimal SUV Threshold Minimal FNR + FPR at SUV = 2.5 Highest diagnostic accuracy at SUV= 4.5
  • 20. Human observation has higher sensitivity than SUV analysis But SUV has greater value in less experience observer
  • 21. SUV threshold = 2.5 is feasible For differentiating benign from metastatic mediastinal lymph nodes in lung CA patients Sen = 89%, Spec = 84% False - : small metastasis False + : LN inflammation
  • 22. High NPV (96%) if PET –ve ; can omit mediastinoscopy Highest diagnostic accuracy at SUV > 4.5 But SUV = 2.5 cannot applied to LN metastasis in other tumor types Because differ 18F-FDG uptake
  • 23.